SCHEMBL5117638

SCHEMBL5117638

Cc1sc2nc(-n3cncn3)nc(NCc3ccc4c(c3)OCCO4)c2c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
MAPT P10636 1/20 0.47
CHRM4 P08173 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
POLB P06746 1/20 0.44
RAD52 P43351 1/20 0.44
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PDE2A O00408 1/20 0.38
USP2 O75604 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
PPP1CA P62136 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5125462 0.95 ALDH1A1 (0.42) ALDH1A1MAPTCHRM4SMN1; SMN2POLB
SCHEMBL5120030 0.91 CHRM4 (0.42) ALDH1A1MAPTCHRM4SMN1; SMN2POLB
SCHEMBL5128280 0.86 CHRM4 (0.41) ALDH1A1MAPTCHRM4SMN1; SMN2KDM4E
SCHEMBL5128666 0.86 BCDIN3D (0.42) ALDH1A1MAPTSMN1; SMN2POLBRAD52
SCHEMBL5128714 0.86 ALDH1A1 (0.47) ALDH1A1MAPTCHRM4SMN1; SMN2POLB
SCHEMBL5127699 0.86 CHRM4 (0.42) ALDH1A1MAPTCHRM4KDM4EMEN1
SCHEMBL5118869 0.85 CHRM4 (0.43) ALDH1A1MAPTCHRM4SMN1; SMN2KDM4E
SCHEMBL5115157 0.85 ADORA2A (0.42) ALDH1A1CHRM4SMN1; SMN2KDM4ELMNA
SCHEMBL5117633 0.85 ALDH1A1 (0.50) ALDH1A1MAPTCHRM4SMN1; SMN2POLB
SCHEMBL5782312 0.84 HTT (0.45) ALDH1A1MAPTCHRM4SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
EP-1685136-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 2006-08-02 EP disclosed
WO-2005047292-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 2005-05-26 WO disclosed
EP-0920431-B1 THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6133271-A Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 2000-10-17 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed
EP-0920431-A1 THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 1999-06-09 EP disclosed
WO-1998006722-A1 THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 ALDH1A1 1055/4885MAPT 2997/4885CHRM4 4573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.